Carglumic Acid Market

Executive Summary

Carglumic Acid Market was valued at US $142.25 million in 2021 and is projected to grow at 7.77% CAGR over the forecast period to reach US $222.84 million by 2027. Carglumic Acid Market represented US $19.77 million opportunity over 2019-2021 and estimated to create US $80.59 million opportunity in 2027 over 2021.

Carglumic Acid from Consainsights analyses the Carglumic Acid Market in the Life Sciences industry over the forecast period to 2027.

Carglumic Acid research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Carglumic Acid segmentation includes Dosage Form, Distribution Channel and Geography.

Based on the Dosage Form, the Carglumic Acid analysis covers Orally Disintegrating Tablets, Dispersible Tablets, Others.

In Dosage Form segment, Orally Disintegrating Tablets segment has highest cagr growth of 6.88%.

Based on the Distribution Channel, the Carglumic Acid analysis covers Hospital Pharmacies, Retail Pharmacies, E-Commerce Channel.

In Distribution Channel segment, Hospital Pharmacies segment has highest cagr growth of 6.88%.

Based on the region, the Carglumic Acid analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Apothecon Pharmaceuticals Pvt Ltd, Manus Aktteva Biopharma LLP, Recordati Rare Diseases Inc, Dipharma Francis S r l, Civentichem LLC, Dipharma S A, NURAY CHEMICALS, NOVITIUM PHARMA LLC, Suven Life Sciences Limited, Biophore India Pharmaceuticals Pvt Ltd and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Dosage Form

Introduction

In 2021, Orally Disintegrating Tablets segment has the highest revenue of US $80.18 million and is expected to grow at CAGR of 6.88% by 2027 Orally Disintegrating Tablets segment has highest cagr growth of 6.88%.

Orally Disintegrating Tablets

Orally Disintegrating Tablets segment was valued at US $69.04 million in 2019 and is projected to grow at 6.88% CAGR over the forecast period to reach US $125.61 million by 2027. Orally Disintegrating Tablets segment represented US $11.14 million opportunity over 2019-2021 and estimated to create US $45.42 million opportunity in 2027 over 2021.

Dispersible Tablets

Dispersible Tablets segment was valued at US $31.61 million in 2019 and is projected to grow at 6.88% CAGR over the forecast period to reach US $57.50 million by 2027. Dispersible Tablets segment represented US $5.10 million opportunity over 2019-2021 and estimated to create US $20.80 million opportunity in 2027 over 2021.

Others

Others segment was valued at US $21.84 million in 2019 and is projected to grow at 6.88% CAGR over the forecast period to reach US $39.73 million by 2027. Others segment represented US $3.52 million opportunity over 2019-2021 and estimated to create US $14.37 million opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, Hospital Pharmacies segment has the highest revenue of US $74.92 million and is expected to grow at CAGR of 6.88% by 2027 Hospital Pharmacies segment has highest cagr growth of 6.88%.

Hospital Pharmacies

Hospital Pharmacies segment was valued at US $64.51 million in 2019 and is projected to grow at 6.88% CAGR over the forecast period to reach US $117.36 million by 2027. Hospital Pharmacies segment represented US $10.41 million opportunity over 2019-2021 and estimated to create US $42.44 million opportunity in 2027 over 2021.

Retail Pharmacies

Retail Pharmacies segment was valued at US $45.45 million in 2019 and is projected to grow at 6.88% CAGR over the forecast period to reach US $82.68 million by 2027. Retail Pharmacies segment represented US $7.33 million opportunity over 2019-2021 and estimated to create US $29.90 million opportunity in 2027 over 2021.

E-Commerce Channel

E-Commerce Channel segment was valued at US $12.53 million in 2019 and is projected to grow at 6.88% CAGR over the forecast period to reach US $22.80 million by 2027. E-Commerce Channel segment represented US $2.02 million opportunity over 2019-2021 and estimated to create US $8.24 million opportunity in 2027 over 2021.